Report overview
This report contains market size and forecasts of Multiple Sclerosis (MS) Drugs in global, including the following market information:
Global Multiple Sclerosis (MS) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Multiple Sclerosis (MS) Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Multiple Sclerosis (MS) Drugs companies in 2021 (%)
The global Multiple Sclerosis (MS) Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Copaxone (Glatiramer Acetate, Copolymer 1) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Multiple Sclerosis (MS) Drugs include Bayer AG, Bayhill Therapeutics, Biogen Idec, Cinnagen, Daiichi Sankyo, Eli Lilly, Fast Forward Llc, Antisense Therapeutics and Apitope, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Multiple Sclerosis (MS) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Multiple Sclerosis (MS) Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multiple Sclerosis (MS) Drugs Market Segment Percentages, by Type, 2021 (%)
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
Global Multiple Sclerosis (MS) Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multiple Sclerosis (MS) Drugs Market Segment Percentages, by Application, 2021 (%)
RRMS
SPMS
PPMS
PRMS
Global Multiple Sclerosis (MS) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multiple Sclerosis (MS) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Multiple Sclerosis (MS) Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Multiple Sclerosis (MS) Drugs revenues share in global market, 2021 (%)
Key companies Multiple Sclerosis (MS) Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Multiple Sclerosis (MS) Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
